Paediatric Respiratory Disease Therapeutics Market Is Expecting Revolutionary Growth in 2019 and Coming Years

Respiratory diseases that affect the air passages that includes nasal passages, bronchi, trachea, and lungs. Respiratory diseases are the major cause of mortality and morbidity in pediatrics. Children are more prone to respiratory infections as they are highly susceptible to viral infections, and genetic disorders. Due to the rise in pediatric respiratory diseases worldwide, it became a burden for the governments and many children is missing school. According to CDC statistics, the prevalence of childhood asthma increased from 8.7% (2001) to 9.5% (2011). Approximately, 629,000 hospital visits are taken for pediatric asthma, and it cost about US$ 272 Mn for Medicaid/CHIP enrollees in 2010. Government bodies such as National Heart, Lung and Blood Institute conducting workshops with leading experts to understand the effect of epigenetic and environmental factors influence on lung development, pulmonary vascular disease, and personalized medicine development, among others. Furthermore, WHO added asthmatic drugs to its essential medicine list to make accessible to the patients. Companies are collaborating to develop novel drugs that can act on various pediatric respiratory diseases. For instance, in July 2016, Genetech, Inc., a member of the F. Hoffmann-La Roche Ltd, and Novartis AG, developed omalizumab to treat pediatric asthma conditions and it was approved by the U.S. FDA. In June 2016, the U.S. FDA approved Allergan’s drug Teflaro (ceftaroline fosamil) that can treat infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and Streptococcus pneumonia conditions.

Get Sample Copy of this report @ https://www.marketresearchreports.biz/sample/sample/13442

Paediatric Respiratory Disease Therapeutics Market: Drivers and Restraints

Pediatric Respiratory Disease Therapeutics Market is mainly driven by the high prevalence and incidence of respiratory disorders such as asthma, pneumonia, cystic fibrosis, tuberculosis, and among others. According to American Thoracic Society statistics, in 2015, it was estimated that pneumonia accounts for 15% of deaths in children under five years old worldwide. In addition to that, 120 Mn episodes of pneumonia occur every year in children under five years. Active involvement of national and international government bodies to promote the research on drugs that can treat on resistant bacteria is responsible to drive the growth of the market during the forecast period. For instance, in December 2012, TB Alliance received US$ 16.7 Mn from UNITAID to develop formulations for pediatric TB medicine for current and future treatments. However, lack of drugs that can treat cystic fibrosis, viral pneumonia conditions is restraining the growth of the market over the forecast period.

Paediatric Respiratory Disease Therapeutics Market: Segmentation

The global pediatric respiratory disease therapeutics market is classified on the basis of drug class, disease indication, route of administration end user and geography.

Based on drug class, the global pediatric respiratory disease therapeutics market is segmented into the following:

Antibiotics
Corticosteroids
Monoclonal Antibodies
Vaccines
Others

Based on disease indication, the global pediatric respiratory disease therapeutics market is segmented into the following:

Acute Respiratory Infections
Chronic Obstructive Pulmonary Disease (COPD)
Asthma
Tuberculosis (TB)
Lung cancer
Others

Based on route of administration, the global pediatric respiratory disease therapeutics market is segmented into the following:

Oral
Nasal
Parenteral

Based on end user, the global pediatric respiratory disease therapeutics market is segmented into the following:

Hospital Pharmacies
Retail Pharmacies
Mail-order Pharmacies
Others

Request For TOC Report @ https://www.marketresearchreports.biz/sample/toc/13442

Paediatric Respiratory Disease Therapeutics Market: Overview

Development of new drugs and increase patient awareness about pediatric respiratory diseases would create an attractive growth opportunities for the pediatric respiratory disease therapeutics market. Companies are adopting novel formulation strategies to treat pediatric respiratory diseases. For instance, in January 2017, AstraZeneca’s drug SYMBICORT was formulated in pressurized metered-dose inhaler and it was approved by the U.S. FDA to treat asthma in pediatric patients. Hospital pharmacies is expected to hold the highest market share in the pediatric respiratory disease therapeutics market.

Paediatric Respiratory Disease Therapeutics Market: Regional Overview

Region wise, the global Pediatric Respiratory Disease Therapeutics Market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Middle East and Africa. North America dominated the global market for pediatric respiratory disease therapeutics market due to availability of various products and favorable reimbursement policies. Increasing prevalence of pediatric respiratory diseases such as asthma, and pneumonia conditions are expected to drive the growth of the market over the forecast period. Asia-Pacific excluding Japan is expected to have higher CAGR during the forecast period owing to the large pool of population in the region.

Paediatric Respiratory Disease Therapeutics Market: Key Players

Some of the players in global pediatric respiratory disease therapeutics market include Teijin Pharma Limited, Teva Pharmaceutical Industries Ltd., Novartis AG, Genetech Inc., (F. Hoffmann-La Roche Ltd), AstraZeneca, GlaxoSmithKline plc, and Pfizer Inc.,

MRR.BIZ has been compiled in-depth market research data in the report after exhaustive primary and secondary research. Our team of able, experienced in-house analysts has collated the information through personal interviews and study of industry databases, journals, and reputable paid sources.

The report provides the following information:

Tailwinds and headwinds molding the market’s trajectory
Market segments based on products, technology, and applications
Prospects of each segment
Overall current and possible future size of the market
Growth pace of the market
Competitive landscape and key players’ strategies

Get Complete Report @ https://www.marketresearchreports.biz/pharmaceuticals-healthcare-and-medical-devices/13442/paediatric-respiratory-disease-therapeutics-global-market-research-reports

The main aim of the report is to:

Enable key stakeholder’s in the market bet right on it
Understand the opportunities and pitfalls awaiting them
Assess the overall growth scope in the near term
Strategize effectively with respect to production and distribution

MRR.BIZ is a leading provider of strategic market research. Our vast repository consists research reports, data books, company profiles, and regional market data sheets. We regularly update the data and analysis of a wide-ranging products and services around the world. As readers, you will have access to the latest information on almost 300 industries and their sub-segments. Both large Fortune 500 companies and SMEs have found those useful. This is because we customize our offerings keeping in mind the specific requirements of our clients.

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: https://www.marketresearchreports.biz/
Email: sales@marketresearchreports.biz

This release was published on openPR.